Over the past few decades, the survival of esophageal cancer patients has improved owing to early detection and advances in multimodality treatment strategies. Imaging plays an important role in every step in the management of esophageal cancer, including diagnosis, staging, assessment of treatment response, and post-treatment surveillance. In this article, we provide a comprehensive review of the role of imaging in these various time points of esophageal cancer management.
KamangarF.DoresG.M.AndersonW.F.Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the worldJ Clin Oncol2006; 24:2137–2150.
2.
SiegelRLMillerKDJemalA.Cancer statistics, 2015CA Cancer J Clin2015; 65:5–29.
3.
DubeczA.GallI.SolymosiN.Temporal trends in long-term survival and cure rates in esophageal cancer: a seer database analysisJ Thorac Oncol2012; 7:443–447.
4.
MundenR.F.MacapinlacH.A.ErasmusJ.J.Esophageal cancer: The role of integrated ct-pet in initial staging and response assessment after preoperative therapyJ Thorac Imaging2006; 21:137–145.
5.
AJCC Cancer Staging Manual 7th edition. 2010Springer VerlagNew York, NY
BangY.J.Van CutsemE.FeyereislovaA.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trialLancet2010; 376:687–697.
8.
Tumours of the esophagusBosmanF.T.CarneiroF.HrubanR.H.TheiseN.D.World Health Organization Classification of Tumours of the Digestive System4th edition. 2010IARC PressLyon, France15–44.
9.
ChanJ.A.BlaszkowskyL.S.EnzingerP.C.A multicenter phase ii trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaAnn Oncol2011; 22:1367–1373.
10.
IlsonD.H.KelsenD.ShahM.A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagusCancer2011; 117:1409–1414.
11.
MoehlerM.MuellerA.TrarbachT.Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase ii studyAnn Oncol2011; 22:1358–1366.
12.
ShahM.A.JhawerM.IlsonD.H.Phase ii study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinomaJ Clin Oncol2011; 29:868–874.
13.
IyerR.B.SilvermanP.M.TammE.P.Diagnosis, staging, and follow-up of esophageal cancerAJR Am J Roentgenol2003; 181:785–793.
14.
BrownL.M.DevesaS.S.ChowW.-H.Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and ageJ Natl Cancer Instit2008; 100:1184–1187.
15.
Rudiger SiewertJ.FeithM.WernerM.Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patientsAnn Surg2000; 232:353–361.
16.
PuliS.R.ReddyJ.B.BechtoldM.L.Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic reviewWorld J Gastroenterol2008; 14:1479–1490.
17.
KimT.J.KimH.Y.LeeK.W.Multimodality assessment of esophageal cancer: Preoperative staging and monitoring of response to therapyRadiographics2009; 29:403–421.
18.
PongpornsupS.PosriS.TotanarungrojK.Diagnostic accuracy of multidetector computed tomography (MDCT) in evaluation for mediastinal invasion of esophageal cancerJ Med Assoc Thai2012; 95:704–711.
19.
PennathurA.FarkasA.KrasinskasA.M.Esophagectomy for t1 esophageal cancer: Outcomes in 100 patients and implications for endoscopic therapyAnn Thorac Surg2009; 87:1048–1054 discussion 1054–55
20.
WangS.LiaoZ.ChenY.Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experienceJ Thorac Oncol2006; 1:252–259.
21.
Van HagenP.HulshofM.van LanschotJ.Preoperative chemoradiotherapy for esophageal or junctional cancerN Engl J Med2012; 366:2074–2084.
22.
ShahM.A.RamanathanR.K.IlsonD.H.Multicenter phase ii study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol2006; 24:5201–5206.
23.
AnconaE.RuolA.SantiS.Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery aloneCancer2001; 91:2165–2174.
24.
BrucherB.L.BeckerK.LordickF.The clinical impact of histopathologic response assessment by residual tumour cell quantification in esophageal squamous cell carcinomasCancer2006; 106:2119–2127.
25.
MeredithK.L.WeberJ.M.TuragaK.K.Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancerAnn Surg Oncol2010; 17:1159–1167.
26.
SchneiderP.M.BaldusS.E.MetzgerR.Histomorphologic tumour regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classificationAnn Surg2005; 242:684–692.
27.
ChirieacL.R.SwisherS.G.AjaniJ.A.Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiationCancer2005; 103:1347–1355.
28.
LevineE.A.FarmerM.R.ClarkP.Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancerAnn Surg2006; 243:472–478.
29.
LordickF.OttK.KrauseB.J.PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The municon phase ii trialLancet Oncol2007; 8:797–805.
30.
KaraosmanoğluA.D.BlakeM.A.Applications of pet-ct in patients with esophageal cancerDiagn Interv Radiol2012; 18:171–182.
31.
BruzziJ.F.MundenR.F.TruongM.T.PET/CT of esophageal cancer: Its role in clinical managementRadiographics2007; 27:1635–1652.
32.
Van WestreenenH.WesterterpM.BossuytP.Systematic review of the staging performance of 18f-fluorodeoxyglucose positron emission tomography in esophageal cancerJ Clin Oncol2004; 22:3805–3812.
33.
Van VlietE.Heijenbrok-KalM.HuninkM.Staging investigations for oesophageal cancer: A meta-analysisBr J Cancer2008; 98:547–557.
34.
ChattertonB.E.ShonI.H.BaldeyA.Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective studyEur J Nucl Med Mol Imaging2009; 36:354–361.
35.
PintoC.Di FabioF.SienaS.Phase ii study of cetuximab in combination with folfiri in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)Ann Oncol2007; 18:510–517.
36.
JanmaatM.L.Gallegos-RuizM.I.RodriguezJ.A.Predictive factors for outcome in a phase ii study of gefitinib in second-line treatment of advanced esophageal cancer patientsJ Clin Oncol2006; 24:1612–1619.
37.
SunW.PowellM.O'DwyerP.J.Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203J Clin Oncol2010; 28:2947–2951.
38.
ShinagareA.B.JagannathanJ.P.KrajewskiK.M.Liver metastases in the era of molecular targeted therapy: New faces of treatment responseAJR Am J Roentgenol2013; 201:W15–W28.
